Sunday, 1 June 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 01 June 2025
News

Behind the scenes with Jazz GM

Posted 14 May 2025 AM

With a five-strong portfolio of drugs now being commercialised across the country, Jazz Pharmaceuticals has well and truly signalled its commitment to Australia with the company’s ANZ General Manager, Eilis Quinn, sharing what’s been going on behind the scenes.

The latest treatment to reach Australia is Enrylaze, a new Erwinia-derived asparaginase approved by the TGA in April for use as a component of a multi-agent chemotherapeutic regimen for the treatment of Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) in adult and paediatric patients (one month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase in Australia.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (21)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.